Work

Utilization and Outcomes of High-Dose Methotrexate in CNS Lymphoma Patients on Hemodialysis: A Report of 2 Cases

Year: 2026

Type: article

Abstract: Introduction: Patients with end-stage renal disease (ESRD) usually do not receive high-dose methotrexate (HDMTX) therapy due to concerns for increased risk for adverse effects, including bone marrow suppression and mucositis. HDMTX therapy is the standard of care for management of CNS lymphoma, both primary and secondary as well as for managing post-transplant lymphoproliferative disorders involving the CNS. Case Presentation: We report the outcomes of 2 patients with primary CNSL lymphoma on HD who received HDMTX with different dosing strategies. Both patients tolerated treatment well and continue to do well at follow-up. Conclusion: These approaches have not been studied in ESRD, and there is growing interest in developing innovative strategies that enable safe HDMTX administration in patients with ESRD undergoing hemodialysis.

Source: Case Reports in Oncology

DOI: 10.1159/000550253